Publication | Closed Access

Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer

Drug TargetingMedicinePharmacologyValid Antitumor EffectsPharmacotherapyCastration-resistant Prostate CancerAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyDrug Discovery